- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00183716
The Trauma Recovery and Empowerment Model for Treating Post-Traumatic Stress Disorder in Women (TREM)
An Randomized Controlled Trial (RCT) of the Trauma Recovery and Empowerment Model
Study Overview
Status
Intervention / Treatment
Detailed Description
Post-traumatic stress disorder (PTSD) is an anxiety disorder that can develop after exposure to a terrifying event in which grave physical harm occurred or was threatened. Rates of PTSD are extremely high among people with severe mental disorders and such individuals find themselves at increased risk for depression, substance abuse, and poor overall health. In turn, these issues lead to high rates of utilization of mental health services. Unfortunately, there is currently a lack of effective trauma treatments that can be implemented in routine mental health settings. Trauma Recovery and Empowerment Model (TREM) is a group-based intervention that addresses PTSD and other closely related consequences of sexual and physical abuse among women with severe mental disorders. This study will determine the effectiveness of TREM in reducing the severity of PTSD symptoms in women with mental disorders who have experienced sexual or physical abuse.
Participants in this open label study will be randomly assigned to receive either usual care alone or usual care combined with TREM for 18 months. Usual care will include medication, case management, and therapy administered by a primary clinician. Participants assigned to usual care will report to the study site at least once a week, or as often as necessary. Participants assigned to usual care plus TREM will also be assigned to a primary clinician and will receive usual care as often as necessary. In addition, TREM participants will take part in 29 group sessions that will focus on increasing self-esteem and trauma-coping skills and reducing self-blame. PTSD symptom severity, trauma beliefs, depressive symptoms, substance use, and mental health service utilization will be measured at Months 6, 12, and 18 for all participants.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20003
- Community Connections
-
-
Maryland
-
Baltimore, Maryland, United States, 21218
- The North Baltimore Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of physical and/or sexual abuse
- Diagnosis of a severe mental disorder
- Diagnosis of PTSD with a symptom severity score of 21 or higher
Exclusion Criteria:
- Severe developmental disabilities or organic brain damage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 2
Participants will receive usual care
|
Participants will receive usual care for women who have experienced psychological trauma.
|
|
Experimental: 1
Participants will receive Trauma Recovery and Empowerment Model and usual care
|
TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
Participants will receive usual care for women who have experienced psychological trauma.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PTSD symptom severity
Time Frame: Measured at baseline and Months 6, 12, and 18
|
Measured at baseline and Months 6, 12, and 18
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Distorted beliefs
Time Frame: Measured at baseline and Months 6, 12, and 18
|
Measured at baseline and Months 6, 12, and 18
|
|
Depressive symptoms
Time Frame: Measured at baseline and Months 6, 12, and 18
|
Measured at baseline and Months 6, 12, and 18
|
|
Substance use
Time Frame: Measured at baseline and Months 6, 12, and 18
|
Measured at baseline and Months 6, 12, and 18
|
|
Mental health service utilization
Time Frame: Measured at Months 6, 12, and 18
|
Measured at Months 6, 12, and 18
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gregory J. McHugo, PhD, Dartmouth College
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01MH068252 (U.S. NIH Grant/Contract)
- DSIR 83-ATAS (NIMH Program Class Code)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.